1328952-01-7

Basic information

• Product Name: 2-ethylphenyl 4-(3-methyl-2-oxoimidazolidin-1-yl)benzenesulfonate
• Synonyms: 2-ethylphenyl 4-(3-methyl-2-oxoimidazolidin-1-yl)benzenesulfonate
• CAS NO: 1328952-01-7
• Molecular Weight: 360.434
• Mol File: 1328952-01-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-ethylphenyl 4-(3-methyl-2-oxoimidazolidin-1-yl)benzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ethylphenyl 4-(3-methyl-2-oxoimidazolidin-1-yl)benzenesulfonate(1328952-01-7)
• EPA Substance Registry System: 2-ethylphenyl 4-(3-methyl-2-oxoimidazolidin-1-yl)benzenesulfonate(1328952-01-7)

Safety Data

• Hazardous Substances Data: 1328952-01-7(Hazardous Substances Data)

Upstream product

• 3363-68-6 4,5-dihydro-3-methyl-1-phenylimidazol-2(1H)-one 
• 1848-69-7 1-phenylimidazolidin-2-one 
• 7144-13-0 1-(2-chloroethyl)-3-phenylurea 
• 62-53-3 aniline 
• 90-00-6 o-Hydroxyethylbenzene 
• 392691-83-7 4-(3-methyl-2-oxoimidazolidin-1-yl)benzene-1-sulfonyl chloride 

Relevant articles and documents

Activation of Phenyl 4-(2-Oxo-3-Alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells

Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein report the rationale, preparation, biological evaluation, and mechanism of action of phenyl 4-(2-oxo-3-Alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) that are antimicrotubule prodrugs activated by CYP1A1. Although PAIB-SOs are inert in most cells tested, they are highly cytocidal toward several human breast cancer cells, including hormone-independent and chemoresistant types. PAIB-SOs are N-dealkylated into cytotoxic phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates (PIB-SOs) in CYP1A1-positive cancer cells, both in vitro and in vivo. In conclusion, PAIB-SOs are novel chemotherapeutic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast cancer is tailored to the characteristic pattern of CYP1A1 expression observed in a large percentage of human breast tumors.